Your browser doesn't support javascript.
loading
Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy.
Waldrop, Megan A; Moore, Steven A; Mathews, Katherine D; Darbro, Benjamin W; Medne, Livja; Finkel, Richard; Connolly, Anne M; Crawford, Thomas O; Drachman, Daniel; Wein, Nicolas; Habib, Ali A; Krzesniak-Swinarska, Monika A; Zaidman, Craig M; Collins, James J; Jokela, Manu; Udd, Bjarne; Day, John W; Ortiz-Guerrero, Gloria; Statland, Jeff; Butterfield, Russell J; Dunn, Diane M; Weiss, Robert B; Flanigan, Kevin M.
Afiliación
  • Waldrop MA; The Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Moore SA; Department of Neurology, The Ohio State University, Columbus, Ohio, USA.
  • Mathews KD; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
  • Darbro BW; Department of Pathology, The University of Iowa, Iowa City, Iowa, USA.
  • Medne L; Depatment of Pediatrics, The University of Iowa, Iowa City, Iowa, USA.
  • Finkel R; Depatment of Pediatrics, The University of Iowa, Iowa City, Iowa, USA.
  • Connolly AM; Department of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Crawford TO; Department of Neurology, Nemours Children's Hospital, Orlando, Florida, USA.
  • Drachman D; Department of Neurology, Washington University, Saint Louis, Missouri, USA.
  • Wein N; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Habib AA; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Krzesniak-Swinarska MA; The Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Zaidman CM; Department of Neurology, Columbia University, New York, New York, USA.
  • Collins JJ; Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Jokela M; Department of Neurology, Washington University, Saint Louis, Missouri, USA.
  • Udd B; Department of Pediatric Neurology, Mercy Hospitals, Springfield, Missouri, USA.
  • Day JW; Neuromuscular Research Center, Tampere University Hospital and University of Tampere, Tampere, Finland.
  • Ortiz-Guerrero G; Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland.
  • Statland J; Neuromuscular Research Center, Tampere University Hospital and University of Tampere, Tampere, Finland.
  • Butterfield RJ; Department of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
  • Dunn DM; Department of Neurology, University of Kansas, Kansas City, Kansas, USA.
  • Weiss RB; Department of Neurology, University of Kansas, Kansas City, Kansas, USA.
  • Flanigan KM; Department of Pediatrics, The University of Utah School of Medicine, Salt Lake City, Utah, USA.
Hum Mutat ; 43(4): 511-528, 2022 04.
Article en En | MEDLINE | ID: mdl-35165973
ABSTRACT
DMD pathogenic variants for Duchenne and Becker muscular dystrophy are detectable with high sensitivity by standard clinical exome analyses of genomic DNA. However, up to 7% of DMD mutations are deep intronic and analysis of muscle-derived RNA is an important diagnostic step for patients who have negative genomic testing but abnormal dystrophin expression in muscle. In this study, muscle biopsies were evaluated from 19 patients with clinical features of a dystrophinopathy, but negative clinical DMD mutation analysis. Reverse transcription-polymerase chain reaction or high-throughput RNA sequencing methods identified 19 mutations with one of three pathogenic pseudoexon types deep intronic point mutations, deletions or insertions, and translocations. In association with point mutations creating intronic splice acceptor sites, we observed the first examples of DMD pseudo 3'-terminal exon mutations causing high efficiency transcription termination within introns. This connection between splicing and premature transcription termination is reminiscent of U1 snRNP-mediating telescripting in sustaining RNA polymerase II elongation across large genes, such as DMD. We propose a novel classification of three distinct types of mutations identifiable by muscle RNA analysis, each of which differ in potential treatment approaches. Recognition and appropriate characterization may lead to therapies directed toward full-length dystrophin expression for some patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Distrofina / Distrofia Muscular de Duchenne Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Hum Mutat Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Distrofina / Distrofia Muscular de Duchenne Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Hum Mutat Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos